Bone loss in young women with karyotypically normal spontaneous premature ovarian failure

被引:103
作者
Anasti, JN
Kalantaridou, SN
Kimzey, LM
Defensor, RA
Nelson, LM
机构
[1] NICHHD, Sect Womens Hlth, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA
[2] NIH, Ctr Clin, Dept Nursing, Bethesda, MD 20892 USA
关键词
D O I
10.1016/S0029-7844(97)00583-8
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To evaluate the effects of karotypically normal spontaneous premature ovarian failure on femoral neck bone mineral density. Methods: Eighty-nine women with karyotypically normal spontaneous premature ovarian failure who desired fertility were evaluated at a tertiary care academic center and underwent hip and spinal bone density measurements by conventional dual-photon absorptiometry. Seventy-seven of the women (87%) had sought medical advice previously and had taken a variety of estrogen and progestin replacement regimens at least intermittently. The median (range) age was 32 (20-39) years, and the median (range) time since diagnosis was 1.5 (0.5-11) years. Findings were compared with a reference group of 218 regularly menstruating women of similar age. Results: Sixty of the 89 women with premature ovarian failure (67%, 95% confidence interval 57, 77) had a femoral neck bone mineral density more than 1 standard deviation (SD) below the mean of the reference group (P < .001, chi(2) with Yates correction). Even in women in whom the bone mineral density measurement was made within just 1.5 years of the diagnosis, nearly one-half (47%) had a femoral neck bone mineral density more than 1 SD below the mean of the reference group (P < .01). Conclusion: Two-thirds of young women with karyotypically normal spontaneous premature ovarian failure have a femoral neck bone mineral density more than 1 SD below the mean of a reference group. These young women need early education regarding strategies to maintain their bone mass and ongoing medical evaluation to maintain compliance with these strategies.
引用
收藏
页码:12 / 15
页数:4
相关论文
共 20 条
  • [1] [Anonymous], 1984, J R STAT SOC C-APPL
  • [2] RISK FOR DEVELOPING OSTEOPOROSIS IN UNTREATED PREMATURE MENOPAUSE
    BAGUR, AC
    MAUTALEN, CA
    [J]. CALCIFIED TISSUE INTERNATIONAL, 1992, 51 (01) : 4 - 7
  • [3] BERMUDEZ JA, 1993, FERTIL STERIL, V60, P668
  • [4] Effects of hormone therapy on bone mineral density - Results from the postmenopausal estrogen/progestin interventions (PEPI) trial
    Bush, TL
    Wells, HB
    James, MK
    BarrettConnor, E
    Marcus, R
    Greendale, G
    Hunsberger, S
    McGowan, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (17): : 1389 - 1396
  • [5] Characterization of idiopathic premature ovarian failure
    Conway, GS
    Kaltsas, G
    Patel, A
    Davies, MC
    Jacobs, HS
    [J]. FERTILITY AND STERILITY, 1996, 65 (02) : 337 - 341
  • [6] COULAM CB, 1986, OBSTET GYNECOL, V67, P604
  • [7] BONE-DENSITY AT VARIOUS SITES FOR PREDICTION OF HIP-FRACTURES
    CUMMINGS, SR
    BLACK, DM
    NEVITT, MC
    BROWNER, W
    CAULEY, J
    ENSRUD, K
    GENANT, HK
    PALERMO, L
    SCOTT, J
    VOGT, TM
    [J]. LANCET, 1993, 341 (8837) : 72 - 75
  • [8] Routine endocrine screening for patients with karyotypically normal spontaneous premature ovarian failure
    Kim, TJ
    Anasti, JN
    Flack, MR
    Kimzey, LM
    Defensor, RA
    Nelson, LM
    [J]. OBSTETRICS AND GYNECOLOGY, 1997, 89 (05) : 777 - 779
  • [9] LINDSAY R, 1984, OBSTET GYNECOL, V63, P759
  • [10] MAZESS RB, 1987, BONE MINER, V2, P211